|Bid||9.50 x 800|
|Ask||10.98 x 1300|
|Day's range||9.90 - 10.46|
|52-week range||4.11 - 11.24|
|Beta (5Y monthly)||1.55|
|PE ratio (TTM)||N/A|
|Earnings date||09 Aug 2021 - 13 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||31 Oct 2014|
|1y target est||18.40|
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you pick the right...
Shares of Paratek Pharmaceuticals (NASDAQ: PRTK) flew nearly 20% higher on Tuesday, on an otherwise forgettable day for the stock market. Paratek announced that the U.S. Food and Drug Administration (FDA) approved its supplemental New Drug Application (NDA) for the oral-only formulation of Nuzyra to treat adults suffering from community-acquired bacterial pneumonia (CABP), a lung disease. Previously, the FDA had approved Nuzyra in 2018 as a once-per-day oral and intravenous treatment for CABP, in addition to acute bacterial skin skin and skin structure infections (ABSSI).
Participants on today's call are Evan Loh, CEO; Adam Woodrow, president and chief commercial officer; Randy Brenner, chief development and regulatory officer; Michael Bigham, executive chairman; and Sarah Higgins, vice president of finance, controller, and principal accounting officer, will also be available for questions. Before I turn the call over to Evan, I would like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs.